Literature DB >> 27167057

Complex Influence of Gonadotropins and Sex Steroid Hormones on QT Interval Duration.

Guillaume Abehsira1, Anne Bachelot1, Fabio Badilini1, Laurence Koehl1, Martine Lebot1, Clement Favet1, Philippe Touraine1, Christian Funck-Brentano1, Joe-Elie Salem1.   

Abstract

CONTEXT: QT interval duration is longer in women than in men. Sex steroid hormones have inconsistently been suggested to explain this difference. The implication of gonadotropins has never been studied.
OBJECTIVE: We report here the combined influence of sex steroid hormones and gonadotropins on QT interval duration in healthy subjects and patients with congenital adrenal hyperplasia (CAH) as a model of T and progesterone overexpression. DESIGN AND PATIENTS: Eighty-four CAH patients (58 women) and 84 healthy subjects matched and paired for sex and age were prospectively included. Circulating concentrations of 17-OH-progesterone, progesterone, T, estradiol, FSH, and LH were measured concomitantly to the recording of a digitized electrocardiogram.
RESULTS: QTcFridericia (QTcF) was shorter in women with CAH than in control women (404 ± 2 vs 413 ± 2.1 milliseconds; P ≤ .001). 17-OH-progesterone, progesterone, the progesterone/estradiol ratio, and total T were higher in women with CAH than in female controls (P < .05), whereas FSH was lower (P ≤ .05). According to multivariable analysis in all women, the progesterone/estradiol ratio (β = -0.33) and FSH levels (β = 0.34) were related to QTcF (r = 0.5; P < .0001), with no influence of CAH or healthy status. QTcF was not different between CAH (404.7 ± 3.7 milliseconds) or healthy men (396 ± 2.8 milliseconds). For men, QTcF (r = 0.48; P < .01) was negatively related to free T (β = -0.29) and positively to FSH levels (β = 0.34).
CONCLUSION: Cardiac repolarization is influenced by complex interactions between sex steroid hormones and gonadotropins, depending on gender. Our results indicate that the progesterone/estradiol ratio in women, T in men, and FSH in both genders are major determinants of ventricular repolarization with opposite effects on QTc interval.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27167057     DOI: 10.1210/jc.2016-1877

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Progesterone pretreatment reduces the incidence of drug-induced torsades de pointes in atrioventricular node-ablated isolated perfused rabbit hearts.

Authors:  James E Tisdale; Heather A Jaynes; Brian R Overholser; Kevin M Sowinski; Richard J Kovacs
Journal:  J Cardiovasc Electrophysiol       Date:  2019-04-21

2.  Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.

Authors:  Virginie Grouthier; Benedicte Lebrun-Vignes; Andrew M Glazer; Philippe Touraine; Christian Funck-Brentano; Antoine Pariente; Carine Courtillot; Anne Bachelot; Dan M Roden; Javid J Moslehi; Joe-Elie Salem
Journal:  Heart       Date:  2018-05-02       Impact factor: 5.994

3.  Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women.

Authors:  Joe-Elie Salem; Pauline Dureau; Anne Bachelot; Marine Germain; Pascal Voiriot; Bruno Lebourgeois; David-Alexandre Trégouët; Jean-Sébastien Hulot; Christian Funck-Brentano
Journal:  JAMA Cardiol       Date:  2018-09-01       Impact factor: 14.676

4.  Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes.

Authors:  Joe-Elie Salem; Tao Yang; Javid J Moslehi; Xavier Waintraub; Estelle Gandjbakhch; Anne Bachelot; Francoise Hidden-Lucet; Jean-Sebastien Hulot; Bjorn C Knollmann; Benedicte Lebrun-Vignes; Christian Funck-Brentano; Andrew M Glazer; Dan M Roden
Journal:  Circulation       Date:  2019-08-05       Impact factor: 29.690

Review 5.  Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.

Authors:  Jiun-Ruey Hu; Meredith S Duncan; Alicia K Morgans; Jonathan D Brown; Wouter C Meijers; Matthew S Freiberg; Joe-Elie Salem; Joshua A Beckman; Javid J Moslehi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-01-23       Impact factor: 8.311

6.  GENomE wide analysis of sotalol-induced IKr inhibition during ventricular REPOLarization, "GENEREPOL study": Lack of common variants with large effect sizes.

Authors:  Joe-Elie Salem; Marine Germain; Jean-Sébastien Hulot; Pascal Voiriot; Bruno Lebourgeois; Jean Waldura; David-Alexandre Tregouet; Beny Charbit; Christian Funck-Brentano
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

7.  Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes.

Authors:  Pietro Enea Lazzerini; Iacopo Bertolozzi; Maurizio Acampa; Silvia Cantara; Maria Grazia Castagna; Laura Pieragnoli; Antonio D'Errico; Marco Rossi; Stefania Bisogno; Nabil El-Sherif; Mohamed Boutjdir; Franco Laghi-Pasini; Pier Leopoldo Capecchi
Journal:  Front Pharmacol       Date:  2020-05-13       Impact factor: 5.810

Review 8.  Sexual Dimorphisms, Anti-Hormonal Therapy and Cardiac Arrhythmias.

Authors:  Virginie Grouthier; Melissa Y Y Moey; Estelle Gandjbakhch; Xavier Waintraub; Christian Funck-Brentano; Anne Bachelot; Joe-Elie Salem
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

Review 9.  Cardiovascular Toxicities of Androgen Deprivation Therapy.

Authors:  Azariyas A Challa; Adam Christopher Calaway; Jennifer Cullen; Jorge Garcia; Nihar Desai; Neal L Weintraub; Anita Deswal; Shelby Kutty; Ajay Vallakati; Daniel Addison; Ragavendra Baliga; Courtney M Campbell; Avirup Guha
Journal:  Curr Treat Options Oncol       Date:  2021-04-17

10.  Endogenous Testosterone Levels and the Risk of Incident Cardiovascular Events in Elderly Men: The MrOS Prospective Study.

Authors:  Tinh-Hai Collet; Susan K Ewing; Kristine E Ensrud; Gail A Laughlin; Andrew R Hoffman; Paul D Varosy; Marcia L Stefanick; Katie L Stone; Eric Orwoll; Douglas C Bauer
Journal:  J Endocr Soc       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.